RTI Biologics, Inc.
Stock Ticker
Join IR Rolodex

Investment Highlights

Positive changes; Excellent outlook

  • 2007 Pro Forma revenues of ~$150 million
  • Last five quarters growth rate of 30 percent
  • Outpacing market growth – market share gains
  • Merger cost synergies identified ~$6.5 - $7.0 million
  • Strength in worldwide tissue sourcing
  • Outlook for continued revenue, earnings and cash flow increases
  • Expected revenue growth ~ 25 percent for FY:08
Web Design by 352 Media Group®. Copyright ©2006 RTI Biologics, Inc. All Rights Reserved. Privacy Policy.